Concepedia

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

Bella Kaufman, Maureen Trudeau, Ahmad Awada, Kimberly Blackwell, Thomas Bachelot, Vanessa Salazar, Michelle DeSilvio, Ronald Westlund, Tal Zaks, Neil L. Spector,

The Lancet Oncology · 2009 · 118 citations · 25 references

DOIFull text

Open access

Concepts

References

25

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou et al. · Cancer Cell · 2004 · 1.8K citations · Full text

, , +12

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Yen‐Yu Lu, Xiaolin Zi, Yuqing Zhao et al. · JNCI Journal of the National Cancer Institute · 2001 · 885 citations · Full text

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 737 citations

, , +16

Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute

Kenneth W. Hance, William F. Anderson, Susan S. Devesa et al. · JNCI Journal of the National Cancer Institute · 2005 · 695 citations · Full text

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith et al. · Oncogene · 2002 · 664 citations

, , +8